Ruxolitinib in Seborrheic Dermatitis

Inclusion Criteria

• •Male or female subjects ≥ 18 years of age at the time of signing the informed consent document.
• •Subject is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures.
• •Subject is able to adhere to the study visit schedule and other protocol requirements.
• •Baseline SD score of IGA ≥ 3 with facial involvement
• •Subject agrees to discontinue all treatments for SD from screening through study completion aside from the study drug
• •Subject has failed an adequate course of treatment with at least one available therapy (topical antifungals or low-potency topical corticosteroids)
• •Subject is judged to be in otherwise good overall health as judged by the investigator, based on medical history, physical examination, and laboratory testing. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).
• •Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on the study drug and for at least 90 days after the last application of the study drug, male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
• •* Option 1: Any one of the following highly effective contraceptive methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy, OR:
• •* Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural \[animal\] membrane \[for example, polyurethane\]); PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
• •The female subject's chosen form of contraception must be effective by the time the female subject is enrolled into the study.
• •Male or female subjects ≥ 18 years of age at the time of signing the informed consent document.
• •Subject is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures.
• •Subject does not currently have and does not have a history of SD.
• •Female of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline